Biden Admin Bars Using Medical Records to Investigate Out-of-State Abortions

As world institutions aim toward a carbon-free future, it is essential to recognize the crucial role that carbon has played in life and innovation.

The law has long shielded tech giants. Ethan Zuckerman’s lawsuit wields it against Meta.

One user said: "Grandma's are literally the worst best thing."

King Charles will not see Prince Harry in London, but he has a "very good opportunity" to make up for it, an expert told Newsweek.

"She's pretty smart, though. I'll give her that," the dog's owner said in the viral video with more than 600,000 views.

The SS Tilawa was carrying hundreds of passengers and thousands of silver bars when it sank in 1942.

"Please be careful my stomach sank when I saw you were tubing in a harbor - sharks are drawn there," a viewer wrote.

The 49-year-old host of “The Drew Barrymore Show” just listed the converted barn estate is listed for $8,450,000.

A pair of Chinese navy warships have embarked on another Pacific operation, Japan says.

Bodil Janssen received an unexpected insight into a rare condition she was born with after eating a carrot in a bar in the Netherlands.

Chaotic video footage captured a brawl that broke out on a long-haul flight from Taiwan to California when one passenger stole the other’s seat. The fight broke out between two passengers mere hours into an 11.5-hour lengthy journey on May 7 when one of them decided to switch seats because his neighbor was coughing —...

Kamala Harris' approval ratings have slightly risen in recent months as she has hit the campaign trail.

The Mets face Sonny Gray and the Cardinals for the second time in 10 days, hoping for better results this time.

"I love these, I don't know why. It's just such a cool deposit of history," said one commenter.

FTX says that nearly all of its customers will receive the money back that they are owed, two years after the cryptocurrency exchange imploded, and some will get more than that

TikTok filed a lawsuit over U.S. legislation that could ban the social media app. It says a new law demanding it sever ties with the Chinese government is unconstitutional and is a free speech issue. However, supporters of the law say it's essential for national security.

Unseasonably high temperatures are scorching the state this week.

The head of a Hamas-cheering radical activist group was among the dozens nabbed when cops cleared out an anti-Israel encampment at the Fashion Institute of Technology in Manhattan, The Post has learned. Manolo De Los Santos, 35, was spotted being hauled away by two NYPD officers in riot helmets near the West 27th Street campus on Tuesday....

Michael Douglas is no stranger to sex scenes and on the edge of 80, the star is sharing his thoughts on onscreen intimacy.

"We hope to have an important impact on this flow of homelessness in our state," said a woman who has helped migrants since 2023.

The government sends out benefits weekly depending on when your birthday is during the month and how long you've been receiving benefits.

The costs take into account the loss of 12,000 cattle across farmlands and ranches, as well as infrastructure repair across the area.

Longevity research may not let us live forever — but it could still make our lives better in smaller ways. Jonathan An tries to ignore the hype about new life-extension treatments, but it’s caught up to him anyway. He has heard the gospel of the longevity influencers, including that one multimillionaire who has been on a media campaign for months claiming that the 111 pills he takes each day will help him live forever. An, an assistant professor of oral sciences at the University of Washington, doesn’t buy it. But he recently found himself inadvertently ensnared by the fervor around anti-aging — thanks to his mice. An has studied mice suffering from periodontal disease, a bacterial-induced inflammatory infection of the gums that can lead to tooth loss. Mice (and more than 60 percent of human adults over 65) have to deal with this uncomfortable oral illness — and they don’t have much choice but to cope. When people’s teeth fall out, dentists like An replace them. But he would rather not have to remove so many. While studying for his doctorate in dentistry at the University of Washington, An pursued a joint PhD to research preventive dental measures. He experimented with giving mice chow infused with the drug rapamycin each day to see if it would improve their oral health. It worked. Mice treated for eight weeks with the drug — traditionally used to help prevent organ-transplant rejection — not only experienced delayed symptoms of periodontal disease, but saw regrowth of their tooth-supporting jaw bones. This year, An is planning to test rapamycin in humans. If it has the same effect in adults as it did in mice, people might eventually be able to pick up a drug at the pharmacy that helps them avoid unwanted trips to the dentist’s office. Better dental health would be a pleasant effect, but that’s not why An’s research drew an unusual amount of attention. Because the drug An chose to test was rapamycin, the longevity field took notice. In separate lab experiments over the past decade, rapamycin has been found to extend the lifespan of yeast, nematodes, fruit flies, and mice. It has helped mice delay or reverse immunity decline, muscle decline, cognitive decline, and cancer growth. This string of successes for rapamycin, which belongs to a class of drugs that stifle one biological pathway for cell growth, has caught the eyes of renowned longevity researchers. It’s also attracted the attention of wealthy lifehackers and the clinics, supplement companies, and biotech investors who — out of true belief, opportunism, or a combination — stand to make money from people seeking an elixir for longer life. Since An’s study was published in 2020, longevity clinics from across the country have asked him how they can incorporate rapamycin into their practices. Some scientists consider rapamycin a strong candidate for life-extension purposes both because it has helped lab species live longer and because it has already been approved as an immunosuppressant in humans. Today, doctors can and do prescribe rapamycin for off-label use — including for longevity. An wants to believe that these clinics — part of a fledgling longevity industry that includes between 50 and 800 providers across the US, according to the Wall Street Journal — are genuinely trying to improve their clients’ health. But he suspects that may not always be the case. He tells the longevity crowd what he does know, which is less exciting than they might hope. When it comes to human health, “I don’t know what rapamycin does,” he said. “But I always tell them to make sure to have a dentist on hand because some of the side effects are oral-related.” Other companies want him to help with their own studies, the results of which they plan to keep private. An says no. “I’m a dentist,” An said. “Not a salesperson.” A longer, healthier life is one of the easiest products in the world to sell. According to a Deloitte report, the 50 biggest longevity companies raised more than $1 billion in venture capital funding as of 2020 — a number that the company said would rise “due to the growing conviction that the longevity market could outstrip the existing health care market.” Altos Labs, a “rejuvenation” biotech whose investors include Jeff Bezos, announced in 2022 that it had raised $3 billion in funding. An astronomer’s discovery of a neutron star has much less commercial potential and therefore generates much less interest than a researcher’s discovery that the micronutrient resveratrol helps yeast live longer — even if it’s likely that neither ultimately affects human lifespan. The attention paid to billionaire-funded research risks obscuring whether the longevity field is genuinely on the verge of a breakthrough or whether a clinic is just saying that to promote their experimental blood transfusion. In reality, longevity research is advancing — but slowly. Clinical trials are moving forward on select uses for longevity drugs, younger researchers are taking the field more seriously, and private organizations are pledging significant support to research: The Saudi-based Hevolution Foundation has promised up to $1 billion in funding annually for biotech startups and academic researchers. But while there likely remain many promising treatment candidates that have yet to be identified, they would take decades to reach clinical trials. Even academics who are bullish on the promise of longevity research fear that, for all the fanfare, the field has become too fixated on a few drugs and lifestyle adjustments that have been under investigation for years, while neglecting the basic research that could reveal novel pathways to slow down human aging. For now, the three best ways to extend your life remain boring: eating a healthy diet, exercising regularly, and sleeping well. We aren’t going to add decades to human life any time soon; living to 150 or 200 remains in the realm of science fiction. But in decades to come, advancements in the science of aging may still lead to therapeutic breakthroughs that lengthen human healthspan — the period of life spent in good health. Perhaps a few more people will become centenarians, but the real success would be having more years when you can live well. How longevity went mainstream in academia Matt Kaeberlein, a longevity researcher at the University of Washington, remembers a time when few in academia took the study of aging — much less the idea of longevity — seriously. “When I came into the field as a graduate student in 1998, there was nobody who went to graduate school to study aging,” he said. “The perception among the broader scientific community was that it was mostly snake oil and crap. There’s still a lot of snake oil and crap, but it is more accepted now than it used to be.” The field began gaining wider recognition in 1993 when Cynthia Kenyon, a pioneer in aging research who now works at the Alphabet-owned life sciences company Calico Labs, discovered that mutating a single gene of the roundworm Caenorhabditis elegans doubled its lifespan. Other scientists soon figured out why. Gary Ruvkun, a professor of genetics at Harvard Medical School, and his colleagues found that the altered gene regulated an insulin-signaling pathway similar to one in humans that might play a role in slowing cell growth and metabolism. Researchers like Andrzej Bartke found similar mechanisms in mice, which have been the subject of much of the relevant research so far. “One of the key things that’s happened is that the evidence that you can actually slow down and interfere with the aging process in mammals … has become so overwhelming that only the willfully blind can ignore it,” Richard A. Miller, who leads the University of Michigan’s Paul Glenn Center for Biology of Aging Research, told me. In the last two decades, scientists have performed hundreds of lab experiments — mostly on animals — on drugs like rapamycin, canagliflozin, acarbose, empagliflozin, metformin, and on interventions like calorie restriction in diets and removal of nondividing senescent cells. Instead of testing the effects of these treatments on specific illnesses, many of these studies test whether certain interventions slow down animals’ aging processes and help them live longer. The expansion of longevity research has unearthed some potentially useful information about which biological mechanisms control aging and how to alter them. In mice and other species, changing a single pathway has the power to extend life by significant margins, raising hopes that if humans respond similarly, certain drugs could extend human lives by years. “We just have a better understanding of what those pathways are,” said Tom Rando, director of the UCLA Broad Stem Cell Research Center, “even if we don’t have a complete understanding of why they work and why they extend lifespan.” Though most experiments with potential longevity drugs and other interventions like blood transfusions are still being tested on lab animals, two dozen candidate drugs have moved to clinical trials with human patients. Daniel Promislow, a University of Washington professor of medicine and pathology, told me that when he got into the field three decades ago, researchers talked hopefully about early developments someday making it to the lab. “Fast forward 25, 30 years, and many of these lab-based discoveries are now at the heart of a large number of clinical trials,” he said. The clinical trials could allow researchers to produce evidence for interventions — besides diet, exercise, and sleep — that might help people live longer. Coleen T. Murphy, professor of molecular biology at Princeton, wrote in her 2023 book How We Age that, “What drugs can I take to live longer?” is becoming an increasingly tangible goal. “A few years ago I might have chuckled at the naivety of this question,” she wrote, “but now it’s not so crazy to think that we will be able to take some sort of medicine to extend our healthy lifespans in the foreseeable future.” The horizon for this future is still far off. Most researchers I spoke to didn’t believe that humans were going to experience a rapid increase in life expectancy any time soon — or maybe ever. They believed progress would instead be made in healthspan, helping people stay healthier for longer and avoiding long periods of physical and cognitive decline as they get older. Such results probably won’t lead to someone living an extra decade. But they could make old age less burdensome. That would matter enormously for individuals, who could enjoy more years in good health, and society, by potentially reducing the high costs of late-in-life medical care. “I can’t fathom saying, ‘Yeah, we’re going to try to extend someone’s lifespan by nine years,’” An told me. “There’s really no way to do that.” Behind the hype, longevity research is moving — but slowly In a way, some of the biggest improvements to human lifespans have already been made. Initiatives in public health — water sanitation, vaccination campaigns, sewage systems — have added decades to the average person’s life over the past few centuries. Since 1900, the average lifespan of a newborn has more than doubled worldwide — from 32 years old to 71 years old. But the very fact that humans already live far longer than a lab animal is part of the reason that longevity research is so slow and difficult. For experimental purposes, laboratory mice live less than three years. Researchers have tested rapamycin in both young and old mice at a range of doses and then waited for them to die. Doing the same in humans would be far more expensive and take much longer. It’s also not strictly legal. The Food and Drug Administration doesn’t classify aging as a disease, which means that clinical trials can’t set out solely to test how much longer an intervention keeps someone alive. Instead, researchers must study age-related indicators like cardiovascular function and cognitive impairment instead of “aging” itself. To compensate, longevity researchers are looking for other ways to measure aging that don’t require a patient’s death. They have identified several biomarkers that could serve as surrogate endpoints, but none have reached a scientific consensus. These include “aging clocks,” predictive models that purport to measure biological age or the age of specific biological organs; Bryan Johnson, the multimillionaire tech founder who calls himself a “professional rejuvenation athlete,” touts such data as proof that he has reversed his aging. These tests are ostensibly based on the research of Steve Horvath, a former professor at UCLA who now works at Altos Labs. He has used age-related DNA methylation to determine biological age. Though most researchers I spoke to expressed cautious optimism about the potential of Horvath’s findings, they were skeptical of the extant consumer tests. “We’re not really sure if the age we tell you is accurate and if it’s going to be the same tomorrow and whether it has any value,” said Tony Wyss-Coray, a Stanford professor of neurology who has found that elderly mice given the blood of younger mice see improvements in brain function. “And of course, no company wants to tell you that, but that’s just a fact.” Most longevity researchers think about their research environment the same way: The flashiest stories are usually pretty removed from the actual state of the field. A drug that just helped mice live 50 percent longer is unlikely to do exactly the same for humans, no matter what a press release implies. Human bodies are much better at repairing their DNA than mice are, which makes them less susceptible to diseases like cancer. Plus, studies that would definitively prove a certain intervention would aid human life would take decades, and experts believe they could struggle to demonstrate their effectiveness to the FDA. “You’ll rarely find a scientist funded by the [National Institutes of Health] who’s doing work in the biology of aging who would claim that their research could or will allow people to live to 140,” Rando told me. “It’s really coalesced around the idea that our main successes will be in reducing the burden of disease.” It reflects a realism among the real experts. In longevity, there is not going to be a moment when a chrysalis bursts and a butterfly flies out, Miller said, a sudden leap forward in people’s life expectancy. “It’s more like the evolution of land plants. Gradually, they creep up over the beach, and then onto the meadow and then into the meadows. This is sort of creeping through the scientific community — too slowly.” According to many researchers, part of the reason for the relatively slow progress in longevity treatments is lack of funding in the field. For all the flashy announcements about companies like Calico and Altos Labs, academic researchers struggle to find financial support. The National Institute on Aging, the NIH division that funds research on the aging process, projects that it will spend about 9 percent of its budget on the biology of aging in 2024 and just under 60 percent on neuroscience-specific research. (The NIA’s total projected budget in 2024 is about $4.4 billion of the NIH’s $47.1 billion.) Promislow and Kaeberlein, who co-run a long-term study on biological and environmental factors that could contribute to aging in dogs, are currently fighting to keep their project alive with their NIH funding expected to end in June. “I think there’s an assumption by a lot of people that there’s a ton of money in aging research,” Murphy told me. “If you’re an academic trying to get funding from the NIH, it’s actually not true.” The lack of funding also draws university researchers out of their scholarly institutions and to companies like Calico and Altos Labs. “The idea of working with very smart people with lots of resources, all that’s really attractive,” Miller told me. But that drift to the private sector could actually slow down aging research, already a sluggish endeavor, even more in the long run. The field is trending toward investor-driven research, while the basic research studies necessary for the next generation of possible interventions languish because they depend on public or philanthropic funding. Drugs like rapamycin have already taken decades to enter clinical trials, but it’s possible that none of the current leading longevity candidates work. Researchers don’t even agree on which of the current drugs and interventions is the most promising: Miller, for example, told me he thinks that rapamycin is “the wrong drug” and that more funding should go to canagliflozin, which has increased median survival age in male mice by 14 percent and for which human side effects are better known due to its use in treating type 2 diabetes since 2013. Still, he doesn’t think it’s easy, “from our limited amount of knowledge, to be confident as to whether rapamycin, or canagliflozin, or any other promising drug would produce major benefits in people with acceptably low side effects.” Most aging-related biotechnology companies use investor money to test aging interventions already proven in mice. Few are conducting the basic research to find new possible pathways for future therapies. The more aging-related pathways scientists can find, the more possible targets for longevity drugs they would have. Each discovery opens the possibility for new interventions. Kaeberlein said that though the field has expanded in terms of the number of studies on certain drugs and mechanistic pathways, it’s also become in a sense more narrow. “We think, ‘This is how the system works. So we’re going to test these parts of the model,’ instead of the more exploratory science that was being done when I was a graduate student, which was, ‘We have no frickin’ clue how the system works. Let’s go do some unbiased screens to figure out what’s happening here,’” he said. Longevity researchers may be playing in a tiny corner of the sandbox, investigating just a few pathways while ignoring other possibilities. Scientists blame such myopia for the long gap between breakthroughs. The most consistently effective intervention for extending animal lifespan has been known for decades: restricting the number of calories they eat. “I think that shift in mentality has led to more incremental results and fewer big, exciting, new discoveries,” said Kaeberlein, “and I think, personally, that’s why nobody has done better than rapamycin in 15 years and no one has done better than caloric restriction in 50 years.” There’s also the possibility that drugs that have worked consistently across different species will work for some humans but not others. “The vast majority of studies in our field are done in one genetically identical strain of mouse,” Rando said. “It’s sort of like running a clinical trial in humans and only using identical twins. … Even if something could work, it’s likely to work in a subset of the population and not in everybody.” Oddly, even the most brazen of the (non-expert) anti-aging boosters have uninspiring perceptions of the current state of longevity research. I was surprised when Bryan Johnson explained to me that, despite having a team of doctors who track the age of his organs and feed him a daily canister of pills, his choices weren’t really made based on today’s advancements in health and wellness. He instead puts his faith in the continued evolution of artificial intelligence capabilities, which has advanced greatly over the past few years. He sees AI continuing to develop at an exponential rate — and longevity research eventually progressing at a more rapid speed than human researchers could hope to replicate. “It’s an observation that we are baby steps away from super intelligence,” Johnson told me, “and it’s improving at a speed that we can’t imagine.” It’s that, he hopes, that will bring about eternal life. The mice studies are less relevant. A more realistic future for the longevity field Immortality is enticing, but it’s not coming anytime soon. Neither is living to 150. Some people — hopefully more than now — will live to 100, but they will still be the exception. The way longevity research might push the field forward could look very similar to the treatments we already have. For people with a high risk of cardiovascular disease, statins are a sort of longevity drug. For those dealing with certain cancers, chemotherapy can be considered a longevity treatment. The future of longevity likely looks more like the world where we discover that rapamycin — a drug that can extend the lives of mice and help humans accept a new organ — can also treat elderly patients for periodontal disease. It could mean that people take a blood sugar-regulating drug like canagliflozin and suffer from fewer heart attacks and cancers. “I don’t really care about life extension because there’s no way to measure it,” An said. “It’s really about your health.” Even in slow motion, the field keeps advancing. Murphy told me she was excited to see trial results from the longevity company Unity Biotechnology back in 2020. The drug UBX0101, which interacts with a tumor-suppressing pathway, cleared a phase 1 clinical trial. When it moved to phase 2, though, it failed to achieve its aim of helping patients with osteoarthritis of the knee. A success could have been a promising sign for treatments to get rid of non-dividing senescent cells. But even a failure was valuable. It might not have been the result that anyone wanted, but it was a result, and it was public. “That’s progress for our field,” she told me. “This is moving forward.”

Arrests were also made hours after dozens left the site and marched to the university's president Ellen Granberg’s home.

"There's no pressure," Bill shared in a new interview. "We're just letting it be what it will be. Because no one is pushing it; there's no turmoil or issues."

The Southern California Independent Bookstore Bestsellers list for Sunday, May 12, 2024, including hardcover and paperback fiction and nonfiction.

With Darvin Ham fired, there are a lot of candidates out there to replace him. But the Lakers seem to be in no rush.

Body camera footage shared by the Hillsborough County Sheriff's office show moments before a deputy-involved shooting early Tuesday morning in Plant City.

As in the original production of “Hair,” getting naked is optional, but now Signature Theatre’s intimacy director is there to help each performer “find a discomfort that’s sustainable for you.”

Sen. John Fetterman (D-PA) walking the halls of Congress. | Nathan Howard/Getty Images Florida Gov. Ron DeSantis banned cell-cultivated or “lab-grown” meat. Why did Democratic Senator John Fetterman lend his support? Last week, Florida Gov. Ron DeSantis signed a bill into law to ban cell-cultivated or “lab-grown” meat from the Sunshine State. “Take your fake lab-grown meat elsewhere,” DeSantis said. “We’re not doing that in the state of Florida.” Cell-cultivated meat is made by feeding animal cells a mix of nutrients to produce real meat without slaughtering an animal. It’s an emerging technology — billed as a solution to factory farming’s enormous carbon footprint and horrific animal treatment — and was approved last June by the US Food and Drug Administration and the US Department of Agriculture as safe to eat and legal to sell. But it remains far from commercial viability and is not available for sale anywhere in the US. DeSantis banned the technology to protect Florida’s farmers and ranchers from future competition. But it was also a culture war win for the governor, as meat has become a hot topic in the right wing’s conspiracy-laden politics. The day DeSantis signed the bill, he posted a bizarre image on X accusing the World Economic Forum of an authoritarian plot to force people to eat cell-cultivated meat. The ban, unsurprisingly, earned DeSantis praise from fellow Republicans. But in a rare moment of political unity, a Democratic member of Congress supported the ban, too: Sen. John Fetterman of Pennsylvania. “Pains me deeply to agree with Crash-and-Burn Ron, but I co-sign this,” Fetterman posted on X, formerly known as Twitter, last week about the Florida ban. “As a member of @SenateAgDems and as some dude who would never serve that slop to my kids, I stand with our American ranchers and farmers.” Pains me deeply to agree with Crash-and-Burn Ron, but I co-sign this. As a member of @SenateAgDems and as some dude who would never serve that slop to my kids, I stand with our American ranchers and farmers. pic.twitter.com/zZLYf8t5lI— Senator John Fetterman (@SenFettermanPA) May 2, 2024 (I’ve tried cell-cultivated chicken and it tastes like, well, chicken — not slop.) This isn’t the first time Fetterman has spoken out against various forms of alternative meat. He’s also co-sponsored a slate of bills supported by factory farm trade groups. Those include bills to ban plant-based egg and dairy companies from using words like “egg” and “dairy,” and to set restrictions on what plant-based meat companies can write on their labels. Fetterman’s office declined an on-the-record interview request for this story and didn’t respond to detailed questions. “The Senator has heard from constituents on this issue, and that’s what informs his views…All of this comes down to consumer choice and transparency,” a spokesperson said in an email, adding that Fetterman has introduced legislation to increase access to soy milk in school cafeterias. The soy milk legislation is important, especially since so many kids can’t digest lactose. But supporting a ban on cell-cultivated meat reduces rather than expands consumer choice. DeSantis’s ban goes against the Republican party’s free market platitudes, though it fits neatly into his culture war agenda. But it may seem odd that Fetterman lent his support. While the Democratic party doesn’t have much to say about meat alternatives, the nascent sector aligns with many of the party’s stated values and goals. Plant- and cell-based meat startups offer an alternative to the factory farm system, which produces virtually all of America’s meat, dairy, and eggs, and is a leading contributor to climate change, air and water pollution, pandemic risk, labor abuse, and animal torture. So why is Fetterman so opposed to slaughter-free meat? If you don’t like cell-cultivated meat factories, you really won’t like factory farms Allying with factory farming business interests will help Fetterman appear more moderate in the swing state of Pennsylvania — the state ranks high in dairy and egg production, and farm-state politicians tend to side with agribusiness. And it’s a move that’s relatively safe for a Democrat to take. Despite the widespread damage that factory farming inflicts on society, Americans of both parties eat lots of meat and dairy. Farmers and ranchers hold a mythic status in American culture, and questioning their practices or calling for even modest regulation is politically dangerous, even for Democrats. Fetterman’s opposition may also be explained by the “naturalistic fallacy”: the notion that anything “natural” — real animals slaughtered for food — is good, while anything new and “artificial,” like cell-cultivated meat, is bad. That was evident in a follow-up to his post in support of DeSantis’s ban, where he shared a picture of a bioreactor used to make cell-cultivated meat with a caption that read “btw, this is the thing that makes lab meat.” btw, this is the thing that makes lab meat pic.twitter.com/4GZIt4SnNN— Senator John Fetterman (@SenFettermanPA) May 3, 2024 Users on X mocked the post, with many sharing photos of similar stainless steel machines used to make all manner of agricultural products, like milk, cheese, beer, and coffee. Some also replied with pictures of factory farms and slaughterhouses — images far more disturbing than a cell-cultivated meat factory. I assume ordinary sausages are made in a manner all would enjoy seeing. https://t.co/Vl2cxp2qkZ— Sridhar Ramesh (@RadishHarmers) May 3, 2024 Any critique of novel food technology must also include an honest reckoning with what it seeks to replace: in this case, conventional meat production, a highly industrialized system that depends on a slew of horrific practices, including: Feeding cattle chicken feces Feeding pigs feces from other pigs Forcibly impregnating animals (this is technically bestiality but most states have exempted it for agricultural purposes) Ripping out female shrimps’ eyes so they lay more eggs Force-feeding ducks Grinding up male chicks alive because they can’t lay eggs This list just skims the surface. Factory farming also commits widespread environmental pollution and subjects its workers to dangerous conditions on the farm and in slaughterhouses, where people lose fingers and limbs and some reportedly wear diapers because bathroom breaks are so limited. Many Democrats side with the factory farming industry. It won’t age well. I’d venture to guess that Fetterman’s membership of the US Senate Agriculture committee should give him a clear picture of what meat, dairy, and egg production entails, so his behavior can likely be chalked up to cold political calculation. Will it work? It’s hard to know what exactly consumers think about cell-cultivated meat, because poll methodology has varied widely, and it’s a hard issue to poll on — most people don’t know what it is and it’s not available for purchase. But we do know that most Americans are uncomfortable with factory farms, and when they have an opportunity at the ballot box to stop its cruelest practices, like locking pigs and egg-laying hens in tiny cages, they tend to take it, whether it’s in a red, purple, or blue state. Animal agriculture accounts for 15 to 20 percent of global greenhouse gas emissions and is under increasing pressure to shrink its environmental footprint. It’s poised to be one of the next fronts in the fight against climate change, and alternative meat technologies could help achieve significant emissions reductions the same way electric vehicles and heat pumps can get us off fossil fuels. While we’ve come to expect Republicans to stand in the way of technological solutions to clean up the environment, Fetterman’s opposition to alternative meat and dairy — and that of others in his party — suggests we may need to brace ourselves for some Democrats to join them. A version of this story originally appeared in the Future Perfect newsletter. Sign up here!

For more than a century, school nurses have improved public health in schools and beyond.

It's not gold, Jerry!

Netflix is keeping things light and fun.

No injuries were reported in the emergency landing at Istanbul Airport.

The U.N. said no humanitarian aid has yet entered and there is no one to receive it on the Palestinian side amid Israel's military incursion.

President Biden marked Holocaust Remembrance Day with a speech Tuesday, supporting Israel. Speaking at the U.S. Capitol, Biden warned that the lessons from the Holocaust are being lost.

Robert Costa and CBS News legal analyst Rikki Klieman break down former President Donald Trump's New York criminal trial after adult film actor Stormy Daniels testifies.

Trump's lawyers let Stormy Daniels give very graphic testimony about her alleged sexual encounter with the former president.

The comedian praised the NFL star's "great joke" about Kanye West, telling Jimmy Kimmel that she "didn't even know we could really go there."

Mel Bouzad/GettyA wealthy heiress and her reality TV producer husband, who own a California home once belonging to Marilyn Monroe, on Monday filed a lawsuit against the city of Los Angeles in an effort to stop the house being designated a landmark—which would prevent them from demolishing it.Brinah Milstein and Roy Bank, who bought the Brentwood property for $8.35 million last summer, were granted a demolition permit from the city, but their plans to tear down the building were temporarily halted by the council in September before the Los Angeles Cultural Heritage Commission recommended historic cultural monument status in January. Milstein and Bank are now attempting to stop the status from going through.In their lawsuit filed in Los Angeles Superior Court, the plaintiffs accused city officials of “illegal and unconstitutional conduct” with respect to the “house where Marilyn Monroe occasionally lived for a mere six months before she tragically committed suicide 61 years ago,” according to KCAL-TV. They also accuse officials of “backdoor machinations” in order to preserve “a house which in no way meets any of the criteria” for a historic cultural monument.Read more at The Daily Beast.

Bankruptcy lawyers say they have collected $14.5 billion to $16.3 billion and are ready to distribute it to defrauded customers.

New York Giants legend Phil Simms did not have his contract renewed by CBS, which he admitted "wasn't a great surprise" after not hearing from them for "a couple months."

The former president said "sleazebags, lowlifes and grifters" can say whatever they want as he slammed his gag order.

L.A. Unified union leaders call Superintendent Alberto Carvalho a liar and a coward. Carvalho says harm to students, workers has been minimized in difficult budget times.

A deep field at Quail Hollow sets the stage for a competitive first round of golf.

Sting's timeless tunes get a fresh flip in the new dance theater production “Message in a Bottle,” which is “sending out an SOS” at the New York City Center through Sunday.

Chaotic video footage captured brave flight attendants stepping in to break up a brawl that erupted between two men aboard a lengthy 11 and a half hour flight from Taiwan to California.

Goldman Sachs appointed the former president of the Federal Reserve Bank of Dallas, Robert Kaplan, as its vice chairman on Tuesday. Kaplan’s new role at the David Solomon-led Wall Street behemoth adds an influential former policymaker and Goldman alum to its management committee. Kaplan, 66, stepped down as the head of the Dallas Fed in September...